Astellas Announces Expiration of HSR Waiting Period for OSI Tender Offer
Tokyo, Japan – March 19, 2010 – Astellas Pharma Inc. (TSE: 4503) today announced that the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Astellas’ proposed acquisition of OSI
Pharmaceuticals Inc. (Nasdaq: OSIP) has expired.
On March 2, 2010, Astellas commenced a tender offer to acquire all of the outstanding shares of OSI for $52.00 per share in
cash. The expiration of the HSR waiting period satisfies one of the conditions of the tender offer. The tender offer is not subject
to any financing conditions or due diligence and only contains customary conditions to close.
Citigroup is acting as exclusive financial advisor to Astellas and Morrison & Foerster LLP is acting as legal counsel.
Further details related to this announcement can be found on www.oncologyleader.com
Brunswick New York
+1 212 333 3810
Brunswick Hong Kong
+852 9850 5033
+ 1 212 440 9872
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around
the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 14,200 employees
organization is committed to becoming a global category leader in urology, immunology & infectious diseases, neuroscience,
DM complications & metabolic diseases and oncology. For more information on Astellas Pharma Inc., please visit our website
at http://www.astellas.com/en .
Important Additional Information
This communication is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer
to sell OSI Pharmaceuticals (“OSI”) common stock. The tender offer (the “Tender Offer”) is being made pursuant to a tender